January 20, 2021

Unlocking efficacy and tolerability of LLD: Continuous immunostimulation enhances lenalidomide (LLD) response

Dr. Mohamad Hussein, Starton Scientific Committee Chair, in an exclusive interview with EBD Group at Biotech Showcase.

Presentations

Starton Therapeutics Overview – JANUARY 2021 ➪

Upcoming Events

—

Past Events

January 14, 2021
Biotech Showcase. WATCH INTERVIEW HERE ➪

October 13, 2020
BIO Investor Forum

September 28, 2020
Virtual CLL Investor Day

Upcoming Events

No upcoming events

Past Events

January 20, 2021

Unlocking efficacy and tolerability of LLD: Continuous immunostimulation enhances lenalidomide (LLD) response

Dr. Mohamad Hussein, Starton Scientific Committee Chair, in an exclusive interview with EBD Group…

September 28, 2020

Virtual CLL Investor Day

Starton Therapeutics is developing STAR-LLD for use in blood cancers including CLL. Topics:Starton continuous…